Biotech · Nasdaq
Vertex Pharmaceuticals
Price data: TradingView widget below
Vertex Pharmaceuticals (VRTX) — Vertex, based in Boston, makes medicines for cystic fibrosis that treat the underlying cause for most patients. It's expanding into pain, kidney disease and gene editing.
Loading chart…
Open VRTX chart in TradingView Affiliate: if you subscribe via our TradingView link, Hodlia may earn a commission at no extra cost to you.
Loading chart…
📐 Technicals
Loading chart…
Indicator summary from TradingView (moving averages, oscillators). A mechanical signal, not advice.
Open technicals in TradingView Affiliate: if you subscribe via our TradingView link, Hodlia may earn a commission at no extra cost to you.
📊 Fundamentals
Loading chart…
🏢 Company profile
Loading chart…
📰 Latest VRTX news
Loading chart…
🧩 What it is
Vertex, based in Boston, makes medicines for cystic fibrosis that treat the underlying cause for most patients. It's expanding into pain, kidney disease and gene editing.
⚡ Why it's interesting
It dominates CF treatment with strong margins and co-developed Casgevy, the first approved CRISPR-based therapy.
⚠️ Key risks
Revenue still depends heavily on CF. New programmes might fail trials, launches like gene therapy are slow and expensive, and drug-pricing pressure is ever present.
👀 What to watch
pain drug launch, kidney-disease trials and CF revenue growth. Diversification beyond CF is the key question.
Written by the Hodlia.fi editorial team. Education only — not financial advice, no price predictions. Contains a TradingView affiliate link.
❓ Vertex Pharmaceuticals FAQ
What is Vertex Pharmaceuticals (VRTX)?
Vertex, based in Boston, makes medicines for cystic fibrosis that treat the underlying cause for most patients. It's expanding into pain, kidney disease and gene editing.
Why do people follow Vertex Pharmaceuticals?
It dominates CF treatment with strong margins and co-developed Casgevy, the first approved CRISPR-based therapy.
What are the main risks of Vertex Pharmaceuticals?
Revenue still depends heavily on CF. New programmes might fail trials, launches like gene therapy are slow and expensive, and drug-pricing pressure is ever present.
What should I watch with Vertex Pharmaceuticals?
pain drug launch, kidney-disease trials and CF revenue growth. Diversification beyond CF is the key question.
Is Vertex Pharmaceuticals a good investment?
Hodlia doesn't give investment advice. Whether Vertex Pharmaceuticals fits you depends on your goals, time horizon and how much loss you can handle. Single stocks can drop a lot even when markets are calm. Read the risks above, compare with a diversified alternative and consider independent advice.